A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor-Reference-Cited by-同舟云学术

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

Published:2014-02-28 Issue:4 Volume:5 Page:908-915
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Burke Russell T¹,Meadows Sarah²,Loriaux Marc M¹³,Currie Kevin S.⁴,Mitchell Scott A.⁴,Maciejewski Patricia⁴,Clarke Astrid S.⁴,Dipaolo Julie A.⁴,Druker Brian J.¹⁵,Lannutti Brian J.²,Spurgeon Stephen E.¹⁶

Affiliation:

1. Knight Cancer Institute, Oregon Health & Science University, Portland, OR

2. Gilead Sciences Inc, Seattle, WA

3. Division of Pathology, Oregon Health & Science University, Portland, OR

4. Gilead Sciences Inc, Branford, CT

5. Howard Hughes Medical Institute, Bethesda, MD

6. Division of Hematology and Medical Oncology, Oregon Health & Science University

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents;Expert Opinion on Investigational Drugs;2024-08-11

2. Recent advancement in pyrrolidine moiety for the management of cancer: A review;Results in Chemistry;2024-01

3. Pyrazine Moiety: Recent Developments in Cancer Treatment;Current Organic Chemistry;2023-05

4. Indazole as a privileged scaffold in drug discovery;Privileged Scaffolds in Drug Discovery;2023

5. Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology;American Journal of Physiology-Cell Physiology;2022-10-01